- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
GNVC Market Currents
more »
-
March 30, 2010 GenVec (GNVC) tumbles 71.9% after it discontinues a trial for its lead gene therapy drug for pancreatic cancer. Interim results showed it was unlikely to become effective.
Comment!
GNVC in Focus
more »
GNVC Related Articles
more »
GNVC News
more »
-
at MarketWatch.com (Dec 29, 2010)
-
at MarketWatch.com (Dec 29, 2010)
GNVC Press Releases and Filings
more »
-
PR Newswire (Fri, 4:00PM)
-
PR Newswire (Mon, 7:30AM)
-
PR Newswire (May 10, 2012)
-
GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012PR Newswire (May 3, 2012)
-
PR Newswire (May 3, 2012)
GNVC Latest Transcript
more »
GNVC Cramer
more »
Currently, there are no Cramer articles on GNVC.
GNVC Instablog posts
more »
GNVC vs. ETF Alternatives
Company Description
GenVec, Inc. (GenVec, we, our, or the Company) is a clinical stage biopharmaceutical company developing novel, gene-based therapeutic drugs and vaccines. Our lead therapeutic product candidate, TNFeradeTM biologic (TNFerade), is being developed for use in the treatment of cancer. TNFerade is... More
